

# Lifetime Cumulative Dose Documentation for Anthracyclines and Bleomycin

---

## 1. Why should we document cumulative doses of anthracyclines?

Anthracyclines, which include **daunorubicin**, **doxorubicin** (including pegylated liposomal), **epirubicin**, **idarubicin** and the anthracenedione **mitoxantrone**, can increase the risk of potentially irreversible cardiac toxicity. This is thought to be caused by mechanisms such as damage to the myocardial tissue by highly reactive free radicals. Cardiotoxicity may manifest as acute (transient) or delayed (progressive). Progressive cardiotoxic effects are dose-related with risk increasing steeply at higher cumulative doses. These effects may present as decreased left ventricular ejection fraction (LVEF) or even symptomatic congestive heart failure (CHF) years after treatment is completed. Since progressive anthracycline-induced cardiotoxicity is related to the total cumulative dose, it is important to monitor a patient's lifetime doses of anthracyclines.<sup>1-7</sup>

Anthracycline drug manufacturers have suggested *maximum lifetime cumulative dose* limits beyond which the risk of cardiotoxicity was seen to substantially increase. Patients should undergo pretreatment assessment and monitoring should start once they approach the monitoring threshold, or at a lower threshold if the patient has pre-existing cardiac or other risk factors. Cancer treatment related risk factors include previous or concurrent therapy with other cardiotoxic drugs such as trastuzumab, cyclophosphamide, and mitomycin, or with high dose mediastinal irradiation to the heart. Other cardiac risk factors include increased age, family history, obesity, diabetes, smoking, hypertension, or preexisting cardiac dysfunction. As patients approach their suggested maximum lifetime cumulative dose, the risk vs. benefit of ongoing treatment must carefully be considered, and further cardiac assessment may be warranted.<sup>1-7</sup>

The doxorubicin monograph in the Cancer Drug Manual contains information on anthracycline cardiotoxicity, monitoring thresholds, conversion factors and management. Pharmacists may be asked to convert cumulative dose from one anthracycline to another. The table below provides a guide for the cumulative dose thresholds at which to start cardiac monitoring in adults with normal cardiac function at baseline. **Lower monitoring thresholds may be used for patients with additional cardiac risk factors.** Note that individual patient sensitivity to anthracycline-induced cardiac toxicity varies, and patients may tolerate lower or higher cumulative doses.

**Table 1: Recommended Anthracycline Conversion Factors & Lifetime Cumulative Dose Monitoring Thresholds for Adults\***

Drug	Conversion Factor to Doxorubicin dose <sup>19</sup>	Suggested Monitoring Threshold <sup>19</sup>	Comments
<b>DAUNOrubicin</b>	x 0.5	450 mg/m <sup>2</sup>	Suggested lifetime limit: 900 mg/m <sup>2</sup> or 25 mg/kg <sup>8</sup> Conversion factor decreased from 0.83 to 0.5**
<b>DAUNOrubicin in DAUNOrubicin-cytarabine liposome (VYXEOS®)</b>	Same as conventional DAUNOrubicin	Same as conventional DAUNOrubicin	Suggested lifetime limit: 550 mg/m <sup>2</sup> (400 mg/m <sup>2</sup> in patients who received mediastinal irradiation) <sup>9</sup> Conversion factor decreased from 0.83 to 0.5**
<b>DOXOrubicin</b>	x 1	300 mg/m <sup>2</sup>	Suggested lifetime limit: 550 mg/m <sup>2</sup> (3 week cycle), 700 mg/m <sup>2</sup> (1 week cycle) <sup>1</sup>
<b>DOXOrubicin, Pegylated Liposomal</b>	Unknown	Unclear relationship between cumulative dose and cardiotoxicity. 400-450 mg/m <sup>2</sup> <sup>10</sup>	No lifetime limit suggested Cardiac toxicity seen at doses above and below 550 mg/m <sup>2</sup> , although less common than with conventional doxorubicin. More common in patients with previous anthracycline exposure, mediastinal radiation, or other cardiac risk factors. Doses exceeding 2000 mg/m <sup>2</sup> tolerated in some patients. Routine baseline and ongoing LVEF assessment have been suggested. <sup>11,12</sup>
<b>Epirubicin</b>	x 0.67	600 mg/m <sup>2</sup>	Suggested lifetime limit: 720-1000 mg/m <sup>2</sup> Risk increases more steeply above 900 mg/m <sup>2</sup> <sup>13</sup>
<b>IDArubicin</b>	x 5	150 mg/m <sup>2</sup>	No lifetime limit suggested IV doses: Cardiomyopathy was reported in 5% of patients who received cumulative IV doses of 150-290 mg/m <sup>2</sup> . PO doses: Cumulative PO doses up to 400mg/m <sup>2</sup> had low probability of cardiotoxicity. <sup>14</sup>
<b>MitoXANTRONE</b>	x 10	140 mg/m <sup>2</sup>	Suggested lifetime limit: 160 mg/m <sup>2</sup> <sup>1</sup> Conversion factor increased from 4 to 10**
*Lower monitoring thresholds and maximum cumulative doses may be used for patients with cardiac risk factors			
**The conversion factors used to calculate doxorubicin equivalent doses in CST Cerner for daunorubicin and mitoxantrone were updated on Mar 3, 2025 to align with Children’s Oncology Group long-term follow up guidance <sup>7, 19</sup>			

# Pharmacy FAQ


## 2. Why should we document cumulative doses of bleomycin?

**Bleomycin** is another agent for which pharmacists keep a record of cumulative doses. The most serious side effects of bleomycin are respiratory and can occur in 10% of patients. Bleomycin pulmonary toxicity (BPT) can progress to pneumonia, pulmonary fibrosis and death in 1% of patients. Identification of patients with BPT can be very difficult due to the nonspecific signs and symptoms, which can progress subtly and rapidly. Non-specific symptoms include dyspnea, dry cough, basal rales, pleuritic chest pain and fever. Patients may have reduced lung capacities in pulmonary function tests. Risk factors for developing BPT include age over 40 years, compromised pulmonary or renal function, concomitant chest irradiation, concomitant therapy with other cancer drugs (eg., cisplatin, gemcitabine, cyclophosphamide, methotrexate, etc.), smoking history, and a high cumulative dose of bleomycin.<sup>1,16-18</sup>

It is important to maintain a record of the lifetime doses of bleomycin that a patient receives. Pulmonary toxicity is more common in patients over 70 years and risk increases steeply at total doses greater than **400 units** (less for patients with renal or pulmonary impairment). BPT can occur at lower doses when given in combination with other chemotherapy drugs, and BC Cancer protocols such as GOBEP suggest limiting bleomycin total dose to **270 units** in lower risk cases. Bleomycin doses given via intraperitoneal or intrapleural route should be counted as half doses due to their lower systemic absorption. Intravesical doses are considered minimally absorbed.<sup>1,16</sup>

Oxygen therapy may also precipitate or aggravate bleomycin pulmonary toxicity, causing lung injury to occur at lower oxygen concentrations than normal.<sup>1,16-18</sup> The bleomycin monograph describes respiratory effects, management and recommendations for oxygen therapy after treatment, for example when it used in surgical anesthesia. At BC Cancer, patients are given a Medical Alert card to inform other health care providers of lung toxicity risk and sensitivity to oxygen therapy. See below.

**Figure 1. Bleomycin alert card**



### 3. How to document cumulative doses of anthracyclines and bleomycin?

A cumulative dose record for all anthracyclines and bleomycin is kept either electronically (for sites using an electronic health record), or on a paper record located in the physical patient chart.

The dose of anthracycline is added at each cycle. When the patient is getting close to the monitoring threshold (e.g., 300 mg/m<sup>2</sup> for doxorubicin) the physician should be alerted, unless it is the patient's last cycle. The use of alternative anthracyclines, such as epirubicin or liposomal doxorubicin, or a change in administration frequency from every 3 weeks to a lower weekly dose, can reduce the risk of cardiotoxicity.<sup>1,6</sup> For patients who have reached a cumulative dose of 300 mg/m<sup>2</sup> doxorubicin equivalent, therapy with the cardio-protective agent dexrazoxane can be considered.<sup>1,5</sup> [For more information on dexrazoxane, please refer to the [Dexrazoxane FAQ](#)].

The cumulative dose of bleomycin units is similarly added.


See below for examples of documentation of doses for **adult** patients. Pediatric doses are recorded separately, for example on a separate Pediatric Lifetime Cumulative Dosing PowerForm in the CST Cerner electronic health record.


#### Electronic Record

BC sites using CST Cerner view an adult **Lifetime Cumulative Dosing component** that can be accessed from the patient chart via an appropriate workflow page [e.g., ONC/HEM/BMT Workflow (Nursing), Outpatient Chart (Provider), Pharmacist Workflow (Pharmacy, see Figure 2)]. Pegylated liposomal doxorubicin doses are not documented here as there is no conversion factor to calculate doxorubicin equivalent doses.

- Any anthracycline or bleomycin doses given at sites using CST Cerner electronic Medication Administration Record (eMAR) for oncology drugs as of Aug 28, 2024, **automatically** flow into the Lifetime Cumulative Dosing component. This occurs via the Medication Administration Record/Medication Administration Wizard (MAR/MAW), once the nurse signs medication administration in the eMAR.

**Figure 2. Accessing Lifetime Cumulative Dosing component in Pharmacist Workflow\***  
(site using CST Cerner eMAR for oncology drugs)



\*At first time use, the component may have to be added to the Workflow page by clicking on  and selecting Lifetime Cumulative Dosing from the list of Components.

## Lifetime Cumulative Dose Documentation for Anthracyclines and Bleomycin

- Any anthracycline or bleomycin doses given outside of CST Cerner eMAR (External/Historical/CST Site Paper MAR dose administrations) require **manual entry** using the **Lifetime Cumulative Dosing External Administrations PowerForm** (Figure 3) to be included in the Lifetime Cumulative Dosing component (Figure 4).

**Figure 3: Lifetime Cumulative Dosing External Administrations PowerForm**

**Figure 4. Sample Lifetime Cumulative Dosing component display**

Lifetime Cumulative Dosing				
	Total DOXOrubicin Equivalents	MAR/MAW	External	Historical
Anthracyclines	116.71 mg/m <sup>2</sup>	49.71 mg/m <sup>2</sup>	33.50 mg/m <sup>2</sup>	33.50 mg/m <sup>2</sup>
DOXOrubicin	49.71 mg/m <sup>2</sup>	49.71 mg/m <sup>2</sup>	-	-
epirubicin	67.00 mg/m <sup>2</sup>	-	33.50 mg/m <sup>2</sup>	33.50 mg/m <sup>2</sup>

Total epirubicin = 100.00 mg/m<sup>2</sup>  
 Conversion Factor = 0.67  
 DOXOrubicin Equivalents = 67.00 mg/m<sup>2</sup>

The adult **Lifetime Cumulative Dosing (LCD) component** converts anthracycline doses to doxorubicin equivalent doses. Using the epirubicin in Figure 4 as an example, External and Historical doses of epirubicin were manually recorded using the LCD External Administrations PowerForm. They then flowed to the LCD component and displayed as 67 mg/m<sup>2</sup> doxorubicin equivalent dose (total epirubicin dose 100 mg/m<sup>2</sup>), resulting in a total doxorubicin equivalent dose of 116.71 mg/m<sup>2</sup> to date for this patient. When this patient nears the monitoring threshold (e.g., 300 mg/m<sup>2</sup> doxorubicin equivalents) the physician should be alerted, unless it is the patient’s last cycle. Consult the CST Cerner Help topic on [Lifetime Cumulative Dosing Documentation \(Adult Oncology\)](#) for more information.

The conversion factors used to calculate doxorubicin equivalent doses for daunorubicin (including daunorubicin liposomal in VYXEOS) and mitoxantrone were updated in CST Cerner on Mar 3, 2025. Previously documented doses (either pulling from the oncology eMAR or the manual LCD external

## Lifetime Cumulative Dose Documentation for Anthracyclines and Bleomycin

administrations PowerForm) will now apply the new conversion factors when displayed in the LCD component.

### Paper Record

The dose of anthracycline is added at each cycle and the cumulative dose/m<sup>2</sup> is manually calculated based on the most recent BSA (Figure 5). The cumulative dose of pegylated liposomal doxorubicin may also be recorded although the relationship between cumulative dose and cardiotoxicity is unclear. Similarly, cumulative dose units of bleomycin are manually calculated (Figure 6).

See examples of paper lifetime cumulative dose records below.

**Figure 5 Sample paper record for manual recording of cumulative anthracycline doses**

<b><u>Anthracycline Lifetime Cumulative Dose Monitoring</u></b>		
Anthracycline: _____		
Date	Prescribed Dose (mg/m <sup>2</sup> )	Lifetime Cumulative Dose in (mg/m <sup>2</sup> )

**Figure 6 Sample paper record for manual recording of cumulative bleomycin doses**

<b><u>Bleomycin Lifetime Cumulative Dose Monitoring</u></b>		
Date	Prescribed Dose (units)	Lifetime Cumulative Dose (units)

## References:

1. BC Cancer. Cancer Drug Manual Drug Index [Internet]. Vancouver, BC: BC Cancer Agency [updated continuously; accessed 2025 Mar 4]. Available from: <http://www.bccancer.bc.ca/health-professionals/professional-resources/cancer-drug-manual/drug-index>.
2. Neilan T et al. Risk and Prevention of Anthracycline Cardiotoxicity. In: UpToDate, Connor RF (Ed), Wolters Kluwer. [Accessed 2024 Aug 28]
3. Jeremy R. Stone et al., Monitoring for Chemotherapy-Related Cardiotoxicity in the Form of Left Ventricular Systolic Dysfunction: A Review of Current Recommendations. *JCO Oncol Pract* 17, 228-236(2021). DOI:10.1200/OP.20.00924
4. Curigliano G, Cardinale D, Suter T, Plataniotis G, de Azambuja E, Sandri MT, Criscitiello C, Goldhirsch A, Cipolla C, Roila F; ESMO Guidelines Working Group. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. *Ann Oncol*. 2012 Oct;23 Suppl 7:vii155-66. doi: 10.1093/annonc/mds293. PMID: 22997448.
5. Smith LA, Cornelius VR, Plummer CJ, Levitt G, Verrill M, Canney P, Jones A. Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. *BMC Cancer*. 2010 Jun 29;10:337. doi: 10.1186/1471-2407-10-337.
6. Cardiac toxicity associated with anthracyclines [Internet]. eViQ Cancer Treatments Online. Cancer Institute NSW; 2004 Sept 1 [reviewed 2019 Aug 30; cited 2024 Aug 28]; 1667 V.4.
7. Children's Oncology Group. Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers Version 6.0. October 2023.
8. Daunorubicin product monograph. ERFA Canada Inc; Montreal, Canada. Revised: August 2, 2017.
9. VYXEOS<sup>®</sup> product monograph. Jazz Pharmaceuticals Ireland Ltd. Ireland. Revised FEB 28, 2023.
10. CAELYX<sup>®</sup> product monograph (liposomal doxorubicin). Janssen Inc; Toronto, Canada. Revised June 6, 2018.
11. Li XR, Cheng XH, Zhang GN, Wang XX, Huang JM. Cardiac safety analysis of first-line chemotherapy drug pegylated liposomal doxorubicin in ovarian cancer. *J Ovarian Res*. 2022 Aug 16;15(1):96. doi: 10.1186/s13048-022-01029-6. PMID: 35971131; PMCID: PMC9380363.
12. Rafiyath SM, Rasul M, Lee B, Wei G, Lamba G, Liu D. Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: a meta-analysis. *Exp Hematol Oncol*. 2012 Apr 23;1(1):10. doi: 10.1186/2162-3619-1-10. PMID: 23210520; PMCID: PMC3514106.
13. ELLENCE<sup>®</sup> product monograph (epirubicin). Pfizer US; New York. Revised Aug 2020
14. IDARUBICIN<sup>®</sup> product monograph. Pfizer Canada; Kirkland, Quebec. Revised Sep 08, 2022
15. MITOXANTRONE INJECTION USP product monograph. Pfizer Canada; Kirkland, Quebec. Revised October 17, 2018
16. Bleomycin for injection product monograph. Pfizer Canada; Kirkland, Quebec. Revised August 2017
17. Azambuja E, Fleck JF, Batista RG, Menna Barreto SS, Bleomycin lung toxicity: who are the patients with increased risk?, *Pulmonary Pharmacology & Therapeutics*, Volume 18, Issue 5, 2005, Pages 363-366, ISSN 1094-5539.
18. Feldman D et al. Bleomycin-induced Lung Injury. In: UpToDate, Connor RF (Ed), Wolters Kluwer. [Accessed 2024 Aug 28]
19. BC Cancer. Cancer Drug Manual Dose Conversion for Anthracycline Exposure [Internet]. Vancouver, BC: BC Cancer Agency [updated continuously; accessed 2025 Mar 4]. Available from: <http://www.bccancer.bc.ca/health-professionals/professional-resources/cancer-drug-manual>.